Platinum therapy loses its sparkle

Non-platinum therapy for small cell lung cancer may have a better risk-benefit profile than platinum-based therapy, suggests an Australian-led Cochrane Review.

Survival at six, 12 and 24 months was not significantly different between platinum and non-platinum treatment arms, the meta-analysis of 32 studies, involving 6075 patients, reveals.

There was also no difference in terms of overall